Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?

Technology in diabetes is rapidly evolving, with the aim of helping affected people to safely optimize their blood glucose control. New technologies are now considered as an essential tool for managing glycemia predominantly in people with type 1 diabetes, and clinical trials have demonstrated that...

Full description

Bibliographic Details
Main Authors: Erika Pedone, Andrea Laurenzi, Agnese Allora, Andrea Mario Bolla, Amelia Caretto
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2020-10-01
Series:Exploration of Medicine
Subjects:
Online Access:https://www.explorationpub.com/Journals/em/Article/100121
id doaj-d505b06daa02426a9a0394c1ffa9f46d
record_format Article
spelling doaj-d505b06daa02426a9a0394c1ffa9f46d2021-06-24T01:45:06ZengOpen Exploration Publishing Inc.Exploration of Medicine2692-31062020-10-011531433010.37349/emed.2020.00021Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?Erika Pedone0https://orcid.org/0000-0002-2588-6528Andrea Laurenzi1https://orcid.org/0000-0002-6073-5098Agnese Allora2Andrea Mario Bolla3https://orcid.org/0000-0001-9366-4081Amelia Caretto4https://orcid.org/0000-0003-1153-6700Vita-Salute San Raffaele University, 20132 Milan, ItalyDepartment of Internal Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, ItalyVita-Salute San Raffaele University, 20132 Milan, ItalyDepartment of Internal Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, ItalyDepartment of Internal Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, ItalyTechnology in diabetes is rapidly evolving, with the aim of helping affected people to safely optimize their blood glucose control. New technologies are now considered as an essential tool for managing glycemia predominantly in people with type 1 diabetes, and clinical trials have demonstrated that in these subjects the use of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems are associated with improved glycemic control along with a better quality of life. Literature regarding technologies and type 2 diabetes is relatively lacking, but innovations may have an important role also in the management of these patients. Some studies in adults with type 2 diabetes have shown benefits with the use of CGM in terms of glycemic variability and improved therapeutic adjustments. Clinical trials about CSII and CGM use in type 2 diabetes may have some pitfalls and future studies are needed to assess how these advanced systems could improve clinical outcomes and also ensure cost-effectiveness in this population. In this narrative review, we aim to highlight the most relevant studies on this topic and to focus on the potential role of new technological devices in type 2 diabetes management.https://www.explorationpub.com/Journals/em/Article/100121continuous glucose monitoringcontinuous subcutaneous insulin infusioncost-effectivenessmultiple daily injectionhypoglycemiatype 2 diabetesdiabetes technology
collection DOAJ
language English
format Article
sources DOAJ
author Erika Pedone
Andrea Laurenzi
Agnese Allora
Andrea Mario Bolla
Amelia Caretto
spellingShingle Erika Pedone
Andrea Laurenzi
Agnese Allora
Andrea Mario Bolla
Amelia Caretto
Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?
Exploration of Medicine
continuous glucose monitoring
continuous subcutaneous insulin infusion
cost-effectiveness
multiple daily injection
hypoglycemia
type 2 diabetes
diabetes technology
author_facet Erika Pedone
Andrea Laurenzi
Agnese Allora
Andrea Mario Bolla
Amelia Caretto
author_sort Erika Pedone
title Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?
title_short Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?
title_full Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?
title_fullStr Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?
title_full_unstemmed Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?
title_sort insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?
publisher Open Exploration Publishing Inc.
series Exploration of Medicine
issn 2692-3106
publishDate 2020-10-01
description Technology in diabetes is rapidly evolving, with the aim of helping affected people to safely optimize their blood glucose control. New technologies are now considered as an essential tool for managing glycemia predominantly in people with type 1 diabetes, and clinical trials have demonstrated that in these subjects the use of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems are associated with improved glycemic control along with a better quality of life. Literature regarding technologies and type 2 diabetes is relatively lacking, but innovations may have an important role also in the management of these patients. Some studies in adults with type 2 diabetes have shown benefits with the use of CGM in terms of glycemic variability and improved therapeutic adjustments. Clinical trials about CSII and CGM use in type 2 diabetes may have some pitfalls and future studies are needed to assess how these advanced systems could improve clinical outcomes and also ensure cost-effectiveness in this population. In this narrative review, we aim to highlight the most relevant studies on this topic and to focus on the potential role of new technological devices in type 2 diabetes management.
topic continuous glucose monitoring
continuous subcutaneous insulin infusion
cost-effectiveness
multiple daily injection
hypoglycemia
type 2 diabetes
diabetes technology
url https://www.explorationpub.com/Journals/em/Article/100121
work_keys_str_mv AT erikapedone insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow
AT andrealaurenzi insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow
AT agneseallora insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow
AT andreamariobolla insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow
AT ameliacaretto insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow
_version_ 1721361857805025280